Hematologic effects of cis-platinum-bleomycin therapy

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Head and neck squamous cell carcinoma is a significant health concern.
• Chemotherapy regimens involving cis-platinum and bleomycin are used for treatment.
• Hematologic side effects of these chemotherapies require careful monitoring.

Purpose of the Study:

• To prospectively evaluate the hematologic findings in patients with head and neck squamous cell carcinoma undergoing treatment with cis-platinum and bleomycin.
• To identify and characterize specific hematologic changes, including potential hemolysis and cytopenias.

Main Methods:

• Prospective study involving 19 patients with head and neck squamous cell carcinoma.
• Administration of cis-platinum (3 mg/kg) on day 1 and bleomycin (15 mg/m2) from day 3 to 10.
• Monitoring of hematologic parameters, including hematocrit, reticulocyte count, and peripheral blood smears.

Main Results:

• All patients experienced a significant decline in hematocrit (mean 41.6 to 36.6, p < 0.001), with the lowest point around day 10.
• Reticulocyte counts remained unchanged.
• One patient exhibited marked hemolysis with spherocytes; 5 others showed spherocytes on blood smears.
• A significant lymphopenia was observed, while neutropenia and thrombocytopenia were absent.

Conclusions:

• Cis-platinum and bleomycin chemotherapy in head and neck cancer patients leads to significant hematologic changes, primarily a decrease in hematocrit.
• The chemotherapy regimen can induce hemolysis, evidenced by spherocytes, in some patients.
• Lymphopenia is a notable hematologic finding, distinct from neutropenia or thrombocytopenia, in this patient cohort.